Episode Synopsis "S19:E3 – Morning Commute Podcast: What Clinicians Should Know about Treatment-Related Adverse Events from HER3-Directed ADCs in Breast and Lung Cancer"

Our faculty continue their discussion about clinical trials of HER3-directed therapies with a look at treatment-related adverse events and how to manage them. Visit www.morningcommutepodcast.com/HER3Agnostic3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

Listen "S19:E3 – Morning Commute Podcast: What Clinicians Should Know about Treatment-Related Adverse Events from HER3-Directed ADCs in Breast and Lung Cancer"

More episodes of the podcast Hematology / Oncology @Point of Care Podcasts

• S18:E2 – Morning Commute Podcast: Embracing HER2-Low, Trop2-Directed, and Other Newer Approaches to HR-Positive Breast Cancer
• S18:E3 – Morning Commute Podcast: Biomarker Testing in HR+ Breast Cancer—If the Shoe Fits
• S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer?
• S19:E2 – Morning Commute Podcast: A Review of Trial Data on HER3 in Non-Small Cell Lung Cancer and Breast Cancer
• S19:E3 – Morning Commute Podcast: What Clinicians Should Know about Treatment-Related Adverse Events from HER3-Directed ADCs in Breast and Lung Cancer
• S20:E1 – Clinical Implications of Trophoblast-Cell Surface Antigen 2 (TROP2) in Non-Small Cell Lung Cancer (NSCLC)
• S20:E2 – Latest Clinical Trial Data of Emerging, TROP2-Targeting Agents in Advanced NSCLC
• S20:E3 – Identifying and Managing Treatment-Related Adverse Events (TRAEs) Associated With TROP2-Targeting Therapies
• S21:E1 – Improving Survival With HMA Maintenance Therapy in AML
• S21:E2 – Individualizing Care Plans for Patients With AML